Nebenwirkungen · Benlysta
Benlysta 120 mg powder for concentrate for solution for infusion. Benlysta 400 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 58
HOS-124014 · Präparat HOS-095751
In a randomised, double-blind, 52-week, post-marketing safety SLE study (BEL115467) which assessed mortality and specific adverse events in adults, serious infections occurred in 3.7 % of patients receiving Benlysta (10 mg/kg body weight intravenously) vs. 4.1 % of patients receiving placebo. However, fatal infections (e.g. pneumonia and sepsis) occurred in 0.45 % (9/2002) of Benlysta-treated patients vs. 0.15 % (3/2001) of patients receiving placebo, while the incidence of all-cause mortality was 0.50 % (10/2002) vs. 0.40 % (8/2001), respectively. Most fatal infections were observed during the first 20 weeks of treatment with Benlysta.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T14:51:00Z · SHA-256 c5a3f583695e2640a8d21bbd8da1102adfb181d1d2a9c5afe0028436c8fd2402 · Passage 21deb8ed01ccbecfa7faefd71611910e5431d0dd1c28f4891618408ee6f88ed6 · Zeichen 8248–8892 im Abschnitt